My (weak) understanding is that the functional impact of a mutation is more important than the type of variations. Otherwise we would see recurrent point mutations rather than hotspots right?

FWIW though, people have already been able to predict treatment outcome from mutation profile. Turns out the hard part is picking up on mutations present in only a tiny subset of the tumor.